company background image
DXB

DimerixASX:DXB Stock Report

Market Cap

AU$81.2m

7D

-1.8%

1Y

-3.6%

Updated

20 Oct, 2021

Data

Company Financials
DXB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

DXB Overview

Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.

Dimerix Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dimerix
Historical stock prices
Current Share PriceAU$0.27
52 Week HighAU$0.17
52 Week LowAU$0.48
Beta1.17
1 Month Change-3.57%
3 Month Change8.00%
1 Year Change-3.57%
3 Year Change145.46%
5 Year Change50.00%
Change since IPO35.00%

Recent News & Updates

Sep 20
Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

CEO Nina Webster has done a decent job of delivering relatively good performance at Dimerix Limited ( ASX:DXB...

May 17
Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

DXBAU BiotechsAU Market
7D-1.8%1.1%1.7%
1Y-3.6%1.7%20.2%

Return vs Industry: DXB underperformed the Australian Biotechs industry which returned 1.7% over the past year.

Return vs Market: DXB underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is DXB's price volatile compared to industry and market?
DXB volatility
DXB Beta1.17
Industry Beta1.62
Market Beta1

Stable Share Price: DXB is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: DXB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2004n/aNina Websterhttps://dimerix.com

Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. The company develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; and DMX-700 that is in pre-clinical development for chronic obstructive pulmonary disease. The company was founded in 2004 and is headquartered in Fitzroy, Australia.

Dimerix Fundamentals Summary

How do Dimerix's earnings and revenue compare to its market cap?
DXB fundamental statistics
Market CapAU$81.24m
Earnings (TTM)-AU$6.37m
Revenue (TTM)AU$4.44m

18.3x

P/S Ratio

-12.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DXB income statement (TTM)
RevenueAU$4.44m
Cost of RevenueAU$0
Gross ProfitAU$4.44m
ExpensesAU$10.81m
Earnings-AU$6.37m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.021
Gross Margin100.00%
Net Profit Margin-143.52%
Debt/Equity Ratio343.9%

How did DXB perform over the long term?

See historical performance and comparison

Valuation

Is Dimerix undervalued compared to its fair value and its price relative to the market?

55.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DXB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DXB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DXB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: DXB is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DXB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DXB is overvalued based on its PB Ratio (55.3x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is Dimerix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dimerix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Dimerix performed over the past 5 years?

-17.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DXB is currently unprofitable.

Growing Profit Margin: DXB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DXB is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.

Accelerating Growth: Unable to compare DXB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: DXB has a negative Return on Equity (-433.89%), as it is currently unprofitable.


Financial Health

How is Dimerix's financial position?


Financial Position Analysis

Short Term Liabilities: DXB's short term assets (A$9.4M) exceed its short term liabilities (A$8.0M).

Long Term Liabilities: DXB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DXB's debt to equity ratio (343.9%) is considered high.

Reducing Debt: Insufficient data to determine if DXB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DXB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DXB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 28.6% each year


Dividend

What is Dimerix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DXB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DXB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DXB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DXB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DXB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average board tenure


CEO

Nina Webster

3.17yrs

Tenure

AU$407,849

Compensation

Dr. Nina Webster, Ph D., BSc (Hons), M IP Law, MBA, has been Chief Executive Offer, Managing Director and Director of Dimerix Limited since August 27, 2018. Dr. Webster served as the Commercial Director of...


CEO Compensation Analysis

Compensation vs Market: Nina's total compensation ($USD304.93K) is about average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Nina's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: DXB's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DXB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.1%.


Top Shareholders

Company Information

Dimerix Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Dimerix Limited
  • Ticker: DXB
  • Exchange: ASX
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$81.236m
  • Shares outstanding: 300.87m
  • Website: https://dimerix.com

Location

  • Dimerix Limited
  • 425 Smith Street
  • Fitzroy
  • Victoria
  • 3065
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:26
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.